Business
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science presentations at Heart Failure 2022, an International Congress of the European Society of Cardiology taking place online and in Madrid, Spain from May 21, 2022 – May 24, 2022. The presentations will include interim data from the open-label extension study of aficamten, REDWOOD-HCM OLE (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) and two additional analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), one on the effect of treatment with omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF) and low blood pressure, and the other on the impact of tricuspid regurgitation on clinical outcomes in patients with HFrEF. Title: GALACTIC-HF - Omecamtiv Mecarbil in HFrEF and Low Blood PressurePresenter: Marco Metra, M.D., Professor of Cardiology & Director of the Institute of Cardiology, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University & Civil Hospitals of Brescia, ItalyDate: May 22, 2022Topic: Chronic Heart Failure Session Title: Late-Breaking Trials - Pharmacological Treatment ISession Type: Late Breaking SciencePresentation Time: 12:13 PM CESTLocation: Room 1 Title: REDWOOD-HCM OLE: Aficamten in HCMPresenter: Ahmad Masri, M.D., Assistant Professor of Medicine, Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science UniversityDate: May 23, 2022Topic: Chronic Heart Failure Session Title: Late-Breaking Trials – Registries and Trial Updates IISession Type: Late Breaking SciencePresentation Time: 5:10 PM CESTLocation: Room 3 Title: GALACTIC-HF and Tricuspid RegurgitationPresenter: Marianna Adamo, M.D., Interventional Cardiologist, University of Brescia, Italy Date: May 23, 2022Topic: Chronic Heart Failure Session Title: Late-Breaking Trials – Registries and Trial Updates IISession Type: Late Breaking SciencePresentation Time: 5:30 PM CESTLocation: Room 3 About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for deb...